Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Phase 2
Terminated
- Conditions
- Lung NeoplasmsMetastatic Lung Non-Small Cell CarcinomaSitravatinibCarcinoma, Non-Small-Cell LungPD-L1 Gene MutationAdvanced Treatment-Naïve PD-L1Lung DiseasesStage IV Lung Non-Small Cell Cancer AJCC v7Pembrolizumab
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sarah Goldberg
- Target Recruit Count
- 9
- Registration Number
- NCT04925986
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
News
No news found